Antibody Drug Conjugates BOC Sciences



March 13, 2019

  • Share
  • Antibody-drug Conjugates or ADCs consist of an antibody, a cytotoxic drug, and a linker that attaches the two. Such conjugates exhibit a broadly applicable method to increase the antitumor activity of antibodies and improve the tumor-to-normal tissue selectivity of chemotherapy. An ideal ADC has a selective monoclonal antibody and a highly potent drug, mixed with properly stable linker systems and conjugation technologies that preserve the characteristics of the antibody. ADCs could theoretically be to target just about any biological tumor target as long as it can be reached by internalizing antibodies.

    Cancer ResearchDrug Discovery

    Keep up to date with all your favourite videos and channels.

    Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.